FI87356C - Foerfarande foer framstaellning av nya xantinderivat - Google Patents

Foerfarande foer framstaellning av nya xantinderivat Download PDF

Info

Publication number
FI87356C
FI87356C FI873704A FI873704A FI87356C FI 87356 C FI87356 C FI 87356C FI 873704 A FI873704 A FI 873704A FI 873704 A FI873704 A FI 873704A FI 87356 C FI87356 C FI 87356C
Authority
FI
Finland
Prior art keywords
formula
compound
compounds
treatment
hydroxy
Prior art date
Application number
FI873704A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI873704A0 (fi
FI87356B (fi
FI873704A (fi
Inventor
Zoltan L Kis
John Morley
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868620825A external-priority patent/GB8620825D0/en
Priority claimed from GB878702129A external-priority patent/GB8702129D0/en
Priority claimed from GB878703435A external-priority patent/GB8703435D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of FI873704A0 publication Critical patent/FI873704A0/fi
Publication of FI873704A publication Critical patent/FI873704A/fi
Application granted granted Critical
Publication of FI87356B publication Critical patent/FI87356B/fi
Publication of FI87356C publication Critical patent/FI87356C/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI873704A 1986-08-28 1987-08-26 Foerfarande foer framstaellning av nya xantinderivat FI87356C (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB868620825A GB8620825D0 (en) 1986-08-28 1986-08-28 Organic compounds
GB8620825 1986-08-28
GB8702129 1987-01-30
GB878702129A GB8702129D0 (en) 1987-01-30 1987-01-30 Organic compounds
GB878703435A GB8703435D0 (en) 1987-02-13 1987-02-13 Organic compounds
GB8703435 1987-02-13

Publications (4)

Publication Number Publication Date
FI873704A0 FI873704A0 (fi) 1987-08-26
FI873704A FI873704A (fi) 1988-02-29
FI87356B FI87356B (fi) 1992-09-15
FI87356C true FI87356C (fi) 1992-12-28

Family

ID=27263135

Family Applications (1)

Application Number Title Priority Date Filing Date
FI873704A FI87356C (fi) 1986-08-28 1987-08-26 Foerfarande foer framstaellning av nya xantinderivat

Country Status (17)

Country Link
EP (1) EP0258191B1 (US20020128544A1-20020912-P00008.png)
JP (1) JPH0631236B2 (US20020128544A1-20020912-P00008.png)
KR (1) KR880002870A (US20020128544A1-20020912-P00008.png)
AU (1) AU600021B2 (US20020128544A1-20020912-P00008.png)
CA (1) CA1289954C (US20020128544A1-20020912-P00008.png)
DE (1) DE3779374D1 (US20020128544A1-20020912-P00008.png)
DK (1) DK169337B1 (US20020128544A1-20020912-P00008.png)
ES (1) ES2033922T3 (US20020128544A1-20020912-P00008.png)
FI (1) FI87356C (US20020128544A1-20020912-P00008.png)
GR (1) GR3004747T3 (US20020128544A1-20020912-P00008.png)
HU (1) HU199840B (US20020128544A1-20020912-P00008.png)
IE (1) IE60512B1 (US20020128544A1-20020912-P00008.png)
IL (1) IL83659A (US20020128544A1-20020912-P00008.png)
MY (1) MY101830A (US20020128544A1-20020912-P00008.png)
NZ (1) NZ221571A (US20020128544A1-20020912-P00008.png)
PH (1) PH24761A (US20020128544A1-20020912-P00008.png)
PT (1) PT85594B (US20020128544A1-20020912-P00008.png)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9210839D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
CA2206804C (en) 1994-12-13 2002-03-19 Euro-Celtique, S.A. Trisubstituted thioxanthines
US6066641A (en) 1994-12-13 2000-05-23 Euro-Celtique S.A. Aryl thioxanthines
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
JP4450365B2 (ja) 2001-08-28 2010-04-14 シェーリング コーポレイション 多環式グアニンホスホジエステラーゼv阻害剤
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP3366698A1 (en) 2011-03-01 2018-08-29 Synergy Pharmaceuticals Inc. Guanylate cyclase c agonists
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP3492106B1 (en) 2013-08-09 2021-02-17 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス, インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1024968B (de) * 1956-03-31 1958-02-27 Asal Fabrik Biolog Und Pharmaz Verfahren zur Herstellung von 7-Ketonyl-8-amino-theophyllinen
AT212847B (de) * 1959-08-13 1961-01-10 Hans Dr Med Voigt Verfahren zur Herstellung des neuen Coffeino-(8)-(β-Phenyl-isopropyl)-amin
FR2157727A1 (en) * 1971-10-29 1973-06-08 Brun Lab Sa Le !,#dimethyl-8-aminopurines - with analgesicantitussive and other theophylline-like activities
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
DE3400951A1 (de) * 1984-01-13 1985-07-18 Robert Bosch Gmbh, 7000 Stuttgart Verfahren und vorrichtung zur drehzahlregelung bei einer brennkraftmaschine
HU197746B (en) * 1985-09-05 1989-05-29 Sandoz Ag Process for producing xantin derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
FI873704A0 (fi) 1987-08-26
HUT47111A (en) 1989-01-30
IE60512B1 (en) 1994-07-27
PT85594B (pt) 1990-05-31
EP0258191B1 (en) 1992-05-27
HU199840B (en) 1990-03-28
FI87356B (fi) 1992-09-15
IE872296L (en) 1988-02-28
IL83659A0 (en) 1988-01-31
DK448787D0 (da) 1987-08-27
ES2033922T3 (es) 1993-04-01
DK448787A (da) 1988-02-29
DK169337B1 (da) 1994-10-10
EP0258191A1 (en) 1988-03-02
IL83659A (en) 1991-06-10
DE3779374D1 (en) 1992-07-02
JPH0631236B2 (ja) 1994-04-27
PT85594A (en) 1987-09-01
AU7744587A (en) 1988-03-03
JPS6363679A (ja) 1988-03-22
AU600021B2 (en) 1990-08-02
NZ221571A (en) 1990-11-27
PH24761A (en) 1990-10-01
KR880002870A (ko) 1988-05-12
FI873704A (fi) 1988-02-29
CA1289954C (en) 1991-10-01
MY101830A (en) 1992-01-31
GR3004747T3 (US20020128544A1-20020912-P00008.png) 1993-04-28

Similar Documents

Publication Publication Date Title
FI87356C (fi) Foerfarande foer framstaellning av nya xantinderivat
RU2060992C1 (ru) Производные дигидроизохинолинов и способ их получения
KR850000301B1 (ko) 페닐에탄올 아민 유도체의 제조 방법
KR0142686B1 (ko) 이소 퀴놀린 유도체, 및 이의 약학적 용도
JPH09508902A (ja) ヒト白血球エラスターゼの阻害剤としてのジアステレオマー純粋なトリフルオロメチルケトンペプチド誘導体
KR102319054B1 (ko) 신규 화합물
AU594363B2 (en) Xathine derivatives, processes for their production and their use in the treatment or prophylaxis of asthma or bronchitis
KR20000064618A (ko) 인돌로모르피난 유도체 및 뇌장해 치료·예방제
SU1421258A3 (ru) Способ получени транс-октагидрооксазоло(4,5 @ )хинолина или его фармацевтически приемлемых солей
FI85481C (fi) Foerfarande foer framstaellning av 2,3 -dihydro-1-(8-metyl-1,2,4-triazolo/4,3-b/pyridazin-6-yl)-4(1h) -pyridinon.
WO1988005775A1 (en) Novel xanthine derivatives
EP0046144B1 (en) Therapeutically active derivatives of phenylethanol amines
US5281605A (en) Novel xanthine derivatives
PL154160B1 (pl) Sposób wytwarzania nowych pochodnych ksantyny
FI88039C (fi) Foerfarande foer framstaellning av 2,3-dihydro-1-(8-metyl-1,2,4-triatsolo/4,3-b/pyridazin-6-yl)-4(1h)-pyridinon
JPS60224690A (ja) d,l‐トランス‐ソブレロールのテオフイリン‐7‐酢酸エステル,ならびにその製造方法および医薬組成物
GB2120250A (en) Enantiomers of 2,3,3a,4,5,6- hexahydro-1H-indolo(3,2,1- de)-[1,5-naphthyridine]
JPH07258247A (ja) シアノアミジン化合物およびその使用
JPH0772168B2 (ja) グアニジノ安息香酸エステル誘導体
SI8111704A8 (sl) Postopek za pripravo etanolaminskih derivatov
MXPA01003047A (en) Tetrahydropyridoethers
JPH09227559A (ja) スピロ置換三環性複素環式化合物

Legal Events

Date Code Title Description
MM Patent lapsed
MM Patent lapsed

Owner name: SANDOZ AG